Evaluation of serum and salivary PCSK9 and IL6 and its association with periodontal inflammation and atherosclerotic cardiovascular diseases

• Published in: Journal of oral biology and craniofacial research (Amsterdam) 2022-09, Vol.12 (5), p.633-638
• Main Authors: Rughwani, Roshan R., Cholan, Priyanka K., Victor, Dhayanand John, Ilango, Paavai, Cherian, Sanjay M., Rughwani, Rajkumar N., Tadepalli, Anupama
• Format: Article
• Language: English
• Subjects: Atherosclerotic cardiovascular disease; Biomarkers; Chronic inflammation; IL6; PCSK9; Periodontal disease; Research Paper
• ISSN: 2212-4268; 2212-4276
• DOI: 10.1016/j.jobcr.2022.08.013

and Purpose: The aim of this study was to assess, compare and correlate the ability of PCSK9 and IL6 as potential common serum and salivary biomarkers for stage III/IV periodontitis and the risk of developing atherosclerotic cardiovascular diseases. 76 patients were alloted into 4 groups consisting of subjects with clinically healthy periodontium and stage III/IV periodontitis with and without ACVD. Clinical parameters – PD, CAL, number of teeth, PI, mSBI, TC, Tg, HDL and LDL were recorded. Serum and saliva samples were obtained and subjected to ELISA for quantifying the biomarker levels. The level of these biomarkers was found to be the lowest (IL6 Serum: 21.92 ± 14.54, IL6 Saliva: 12.34 ± 7.72, PCSK9 Serum: 178.82 ± 35.07, PCSK9 Saliva: 80.82 ± 25.43) in group I and highest in group IV (IL6 Serum: 73.4 ± 24.86, IL6 Saliva: 37.66 ± 15.77, PCSK9 Serum: 346.54 ± 45.11, PCSK9 Saliva: 157.72 ± 43.28). The clinical parameters PI, mSBI, PPD, CAL, total number of teeth, TC, HDL and LDL showed a significant correlation with biomarkers PCSK9 and IL6. This study features the elevation of serum and salivary PCSK9 and IL6 in periodontitis and ACVD. A triad of serum and salivary PCSK9 and IL6 along with the clinical markers of periodontal disease can relatively predict the future risk of developing ACVD. [Display omitted]